Prothena Corp Option Alert: Aug 15 $7.5 Puts at the Ask: 23041 vs 295 OI

Prothena Corp Option Alert: Aug 15 $7.5 Puts at the Ask: 23041 @ $0.4 vs 295 OI; Ref=$7.75

Prothena Corp

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

New,York,,Usa,-,January,07,,2025:,E2open,Website,Displayed

ABEO

BLMZ

CMBM

DGLY

DGNX

ETWO

GORV

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IMNN

IXHL

ONCY

PMAX

PRTA

SBET

SILO

VVPR

WORX

Consulta las acciones con mayores subidas y caídas en el premercado estadounidense de hoy, incluyendo tecnológicas, biotecnológicas y más.

Las acciones de E2open se disparan un 25%; aquí están 20 acciones que se mueven en el premercado

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Prothena Corporation plc - Ordinary Shares

Prothena Corp PLC

Press Releases

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Prothena Announces Corporate Restructuring

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Abeona Therapeutics

Absci

Astria Therapeutics

aTyr Pharma

Aura Biosciences

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Compass Therapeutics, Inc. - Common Stock

Compass Therapeutics

Emergent BioSolutions

Erasca

Gossamer Bio

I-MAB

ITeos Therapeutics

Kamada

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Nanobiotix

PureTech Health plc - American Depositary Shares

PureTech Health

Replimune Group

Regenxbio

Solid Biosciences

Tectonic Therapeutic, Inc. - Common Stock

Tectonic Therapeutic

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Verastem

XOMA Royalty

Y-mAbs Therapeutics

RBC Capital

HC Wainwright & Co.

Chardan Capital

B of A Securities

Piper Sandler

Comments

Prothena Corp

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL